Matteo Bonini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matteo Bonini has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Daniele Bartoli
Department of Mathematics and Informatics, University of Perugia, Perugia, Italy
13 shared publications - Marco Timpanella
Dipartimento di Matematica e Informatica, Università degli Studi di Perugia, Perugia, Italy
5 shared publications - Eimear Byrne
University College Dublin
3 shared publications - Martino Borello
Laboratoire de Géométrie, Analyse et Applications, LAGA, CNRS, UMR 7539, Université Sorbonne Paris Nord, Université Paris 8, Saint-Denis, France
3 shared publications - Massimiliano Sala
University of Trento
3 shared publications - Burçin Güneş
Sabancı University, MDBF, Orhanlı , Tuzla , 34956 Istanbul , Turkey
2 shared publications
Latest Publications
- Open Access
On QC and GQC algebraic geometry codes
We present new constructions of quasi-cyclic (QC) and generalized quasi-cyclic (GQC) codes from algebraic curves. Unlike previous approaches based on elliptic curves, our method applies to curves that are Kummer extensions of the rational function field, including hyperelliptic, norm-trace, and Hermitian curves. This allows QC codes with flexible co-index. Explicit parameter formulas are derived using known automorphism-group classifications.
Open AccessOn QC and GQC algebraic geometry codes
We present new constructions of quasi-cyclic (QC) and generalized quasi-cyclic (GQC) codes from algebraic curves. Unlike previous approaches based on elliptic curves, our method applies to curves that are Kummer extensions of the rational function field, including hyperelliptic, norm-trace, and Hermitian curves. This allows QC codes with flexible co-index. Explicit parameter formulas are derived using known automorphism-group classifications.
- Open Access
- 9 April 2025
- Published by Springer Nature in Designs, Codes and Cryptography
- Vol. 93 (8) , 2993-3009
The geometry of covering codes in the sum–rank metric
We introduce the concept of a sum–rank saturating system and outline its correspondence to covering properties of a sum–rank metric code. We consider the problem of determining the shortest length of a sum–rank- $$\rho $$ -saturating system of a fixed dimension, which is equivalent to the covering problem in the sum–rank metric. We obtain upper and lower bounds on this quantity. We also give constructions of saturating systems arising from geometrical structures.- 9 April 2025
- Published by Springer Nature in Designs, Codes and Cryptography
- Vol. 93 (8) , 2993-3009
Open AccessThe geometry of covering codes in the sum–rank metric
We introduce the concept of a sum–rank saturating system and outline its correspondence to covering properties of a sum–rank metric code. We consider the problem of determining the shortest length of a sum–rank- $$\rho $$ -saturating system of a fixed dimension, which is equivalent to the covering problem in the sum–rank metric. We obtain upper and lower bounds on this quantity. We also give constructions of saturating systems arising from geometrical structures. - Open Access
- 11 December 2024
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 8, e56848
The Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study
Background: Beta-2 agonists play an important role in the management of asthma. Inhaled long-acting beta-2 agonists (LABAs) and short-acting beta-2 agonists (SABAs) cause bronchodilation by stimulating adrenoceptors. These receptors are also present in cardiac cells and, as a side effect, could also be stimulated by inhaled beta-2 agonists. Objective: This study aims to assess the effect of beta-2 agonists on heart rate (HR). Methods: The data were retrieved from an observational study, the myAirCoach Quantification Campaign. Beta-2 agonist use was registered by self-reported monthly questionnaires and by smart inhalers. HR was monitored continuously with the Fitbit Charge HR tracker (Fitbit Inc). Patients (aged 18 years and older) were recruited if they had uncontrolled asthma and used inhalation medication. Our primary outcome was the difference in HR between LABA and non-LABA users. Secondary outcomes were the difference in HR on days SABAs were used compared to days SABAs were not used and an assessment of the timing of inhaler use during the day. Results: Patients using LABA did not have a clinically relevant higher HR (average 0.8 beats per minute difference) during the day. Around the moment of SABA inhalation itself, the HR does increase steeply, and it takes 138 minutes before it returns to the normal range. Conclusions: This study indicates that LABAs do not have a clinically relevant effect on HR. SABAs are instead associated with a short-term HR increase. Trial Registration: ClinicalTrials.gov NCT02774772; https://clinicaltrials.gov/study/NCT02774772
- 11 December 2024
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 8, e56848
Open AccessThe Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study
Background: Beta-2 agonists play an important role in the management of asthma. Inhaled long-acting beta-2 agonists (LABAs) and short-acting beta-2 agonists (SABAs) cause bronchodilation by stimulating adrenoceptors. These receptors are also present in cardiac cells and, as a side effect, could also be stimulated by inhaled beta-2 agonists. Objective: This study aims to assess the effect of beta-2 agonists on heart rate (HR). Methods: The data were retrieved from an observational study, the myAirCoach Quantification Campaign. Beta-2 agonist use was registered by self-reported monthly questionnaires and by smart inhalers. HR was monitored continuously with the Fitbit Charge HR tracker (Fitbit Inc). Patients (aged 18 years and older) were recruited if they had uncontrolled asthma and used inhalation medication. Our primary outcome was the difference in HR between LABA and non-LABA users. Secondary outcomes were the difference in HR on days SABAs were used compared to days SABAs were not used and an assessment of the timing of inhaler use during the day. Results: Patients using LABA did not have a clinically relevant higher HR (average 0.8 beats per minute difference) during the day. Around the moment of SABA inhalation itself, the HR does increase steeply, and it takes 138 minutes before it returns to the normal range. Conclusions: This study indicates that LABAs do not have a clinically relevant effect on HR. SABAs are instead associated with a short-term HR increase. Trial Registration: ClinicalTrials.gov NCT02774772; https://clinicaltrials.gov/study/NCT02774772
- Open Access
- 28 January 2024
- Published by JMIR Publications Inc. in JMIR Preprints
The Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study (Preprint)
BACKGROUND Beta-2 agonists play an important role in the management of asthma. Inhaled long-acting beta-2 agonists (LABAs) and short-acting beta-2 agonists (SABAs) cause bronchodilation by stimulating adrenoceptors. These receptors are also present in cardiac cells and, as a side effect, could also be stimulated by inhaled beta-2 agonists. OBJECTIVE This study aims to assess the effect of beta-2 agonists on heart rate (HR). METHODS The data were retrieved from an observational study, the myAirCoach Quantification Campaign. Beta-2 agonist use was registered by self-reported monthly questionnaires and by smart inhalers. HR was monitored continuously with the Fitbit Charge HR tracker (Fitbit Inc). Patients (aged 18 years and older) were recruited if they had uncontrolled asthma and used inhalation medication. Our primary outcome was the difference in HR between LABA and non-LABA users. Secondary outcomes were the difference in HR on days SABAs were used compared to days SABAs were not used and an assessment of the timing of inhaler use during the day. RESULTS Patients using LABA did not have a clinically relevant higher HR (average 0.8 beats per minute difference) during the day. Around the moment of SABA inhalation itself, the HR does increase steeply, and it takes 138 minutes before it returns to the normal range. CONCLUSIONS This study indicates that LABAs do not have a clinically relevant effect on HR. SABAs are instead associated with a short-term HR increase. CLINICALTRIAL ClinicalTrials.gov NCT02774772; https://clinicaltrials.gov/study/NCT02774772
- 28 January 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study (Preprint)
BACKGROUND Beta-2 agonists play an important role in the management of asthma. Inhaled long-acting beta-2 agonists (LABAs) and short-acting beta-2 agonists (SABAs) cause bronchodilation by stimulating adrenoceptors. These receptors are also present in cardiac cells and, as a side effect, could also be stimulated by inhaled beta-2 agonists. OBJECTIVE This study aims to assess the effect of beta-2 agonists on heart rate (HR). METHODS The data were retrieved from an observational study, the myAirCoach Quantification Campaign. Beta-2 agonist use was registered by self-reported monthly questionnaires and by smart inhalers. HR was monitored continuously with the Fitbit Charge HR tracker (Fitbit Inc). Patients (aged 18 years and older) were recruited if they had uncontrolled asthma and used inhalation medication. Our primary outcome was the difference in HR between LABA and non-LABA users. Secondary outcomes were the difference in HR on days SABAs were used compared to days SABAs were not used and an assessment of the timing of inhaler use during the day. RESULTS Patients using LABA did not have a clinically relevant higher HR (average 0.8 beats per minute difference) during the day. Around the moment of SABA inhalation itself, the HR does increase steeply, and it takes 138 minutes before it returns to the normal range. CONCLUSIONS This study indicates that LABAs do not have a clinically relevant effect on HR. SABAs are instead associated with a short-term HR increase. CLINICALTRIAL ClinicalTrials.gov NCT02774772; https://clinicaltrials.gov/study/NCT02774772
- Open Access
The geometry of covering codes in the sum-rank metric
We introduce the concept of a sum-rank saturating system and outline its correspondence to a covering properties of a sum-rank metric code. We consider the problem of determining the shortest sum-rank-ρ-saturating systems of a fixed dimension, which is equivalent to the covering problem in the sum-rank metric. We obtain upper and lower bounds on this quantity. We also give constructions of saturating systems arising from geometrical structures.
Open AccessThe geometry of covering codes in the sum-rank metric
We introduce the concept of a sum-rank saturating system and outline its correspondence to a covering properties of a sum-rank metric code. We consider the problem of determining the shortest sum-rank-ρ-saturating systems of a fixed dimension, which is equivalent to the covering problem in the sum-rank metric. We obtain upper and lower bounds on this quantity. We also give constructions of saturating systems arising from geometrical structures.
- Open Access
- 28 October 2023
- Published by Elsevier in Finite Fields and Their Applications
- Vol. 93
More on the DLW conjectures
- 28 October 2023
- Published by Elsevier in Finite Fields and Their Applications
- Vol. 93
Open AccessMore on the DLW conjectures
- Open Access
- 18 September 2023
- Published by Springer Nature in Aequationes mathematicae
- Vol. 98 (1) , 333-346
Minimal codewords in Norm-Trace codes
- 18 September 2023
- Published by Springer Nature in Aequationes mathematicae
- Vol. 98 (1) , 333-346
Open AccessMinimal codewords in Norm-Trace codes
- Open Access
Saturating systems and the rank covering radius
We introduce the concept of a rank saturating system and outline its correspondence to a rank-metric code with a given covering radius. We consider the problem of finding the value of $s_{q^m/q}(k,\rho)$, which is the minimum $\mathbb{F}_q$-dimension of a $q$-system in $\mathbb{F}_{q^m}^k$ which is rank $\rho$-saturating. This is equivalent to the covering problem in the rank metric. We obtain upper and lower bounds on $s_{q^m/q}(k,\rho)$ and evaluate it for certain values of $k$ and $\rho$. We give constructions of rank $\rho$-saturating systems suggested from geometry.Open AccessSaturating systems and the rank covering radius
We introduce the concept of a rank saturating system and outline its correspondence to a rank-metric code with a given covering radius. We consider the problem of finding the value of $s_{q^m/q}(k,\rho)$, which is the minimum $\mathbb{F}_q$-dimension of a $q$-system in $\mathbb{F}_{q^m}^k$ which is rank $\rho$-saturating. This is equivalent to the covering problem in the rank metric. We obtain upper and lower bounds on $s_{q^m/q}(k,\rho)$ and evaluate it for certain values of $k$ and $\rho$. We give constructions of rank $\rho$-saturating systems suggested from geometry. - Open Access
- 29 May 2023
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 19 (8) , 1041-1049
Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making
Type 2 targeting biologics have reached the market first for asthma and since 2019 also for CRSwNP. As clear guidelines and predictors for optimal biological choice are missing, patients are sometimes required to switch biologic therapy in order to find the optimal treatment result. In this paper, we evaluate reasons for switching biologics and the treatment effects after each sequential switch. Ninety-four patients who switched from one biologic to another for their treatment of CRSwNP and asthma were evaluated. Twenty patients experienced satisfactory control of CRSwNP, but insufficient control of severe asthma. Fifty-one patients experienced satisfactory control of severe asthma, but insufficient control of CRSwNP/EOM. Twenty-eight patients experienced insufficient control of both upper and lower airways. Thirteen patients had to switch because of side effects. Furthermore, two cases are described to clarify clinical decision-making. For abovementioned patients, a multidisciplinary approach is mandatory to find the best suitable biologic. It seems ineffective to switch to a second anti-IL5 treatment if the first one is not successful. Most patients that failed omalizumab and/or an anti-IL-5 treatment are well controlled on dupilumab. Therefore, we suggest to use dupilumab as first choice when switching biologic agents.
- 29 May 2023
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 19 (8) , 1041-1049
Open AccessEvaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making
Type 2 targeting biologics have reached the market first for asthma and since 2019 also for CRSwNP. As clear guidelines and predictors for optimal biological choice are missing, patients are sometimes required to switch biologic therapy in order to find the optimal treatment result. In this paper, we evaluate reasons for switching biologics and the treatment effects after each sequential switch. Ninety-four patients who switched from one biologic to another for their treatment of CRSwNP and asthma were evaluated. Twenty patients experienced satisfactory control of CRSwNP, but insufficient control of severe asthma. Fifty-one patients experienced satisfactory control of severe asthma, but insufficient control of CRSwNP/EOM. Twenty-eight patients experienced insufficient control of both upper and lower airways. Thirteen patients had to switch because of side effects. Furthermore, two cases are described to clarify clinical decision-making. For abovementioned patients, a multidisciplinary approach is mandatory to find the best suitable biologic. It seems ineffective to switch to a second anti-IL5 treatment if the first one is not successful. Most patients that failed omalizumab and/or an anti-IL-5 treatment are well controlled on dupilumab. Therefore, we suggest to use dupilumab as first choice when switching biologic agents.
- Open Access
Minimal codewords in Norm-Trace codes
In this paper, we consider the affine variety codes obtained evaluating the polynomials $by=a_kx^k+\dots+a_1x+a_0$, $b,a_i\in\mathbb{F}_{q^r}$, at the affine $\F_{q^r}$-rational points of the Norm-Trace curve. In particular, we investigate the weight distribution and the set of minimal codewords. Our approach, which uses tools of algebraic geometry, is based on the study of the absolutely irreducibility of certain algebraic varieties.Open AccessMinimal codewords in Norm-Trace codes
In this paper, we consider the affine variety codes obtained evaluating the polynomials $by=a_kx^k+\dots+a_1x+a_0$, $b,a_i\in\mathbb{F}_{q^r}$, at the affine $\F_{q^r}$-rational points of the Norm-Trace curve. In particular, we investigate the weight distribution and the set of minimal codewords. Our approach, which uses tools of algebraic geometry, is based on the study of the absolutely irreducibility of certain algebraic varieties.